A paper published this month proving that the use of RNA transposons can improve the CRISPR process has excited the ...

For several years, trends in modern medicine have been shifting towards promising treatments in cell and gene therapy. Backing these ...

On April 11, I attended the NC Tech Talk Live panel discussion on Cybersecurity Metrics in the very impressive WeWork ...

Clinical trials have long been viewed as complicated and high-volume endeavors, involving the widespread recruitment of patients, supply chain planning ...

The most innovative organizations have demonstrated their success stems from creative strategy paired with iterative and efficient execution. It’s all ...

Underlying all of the widespread uses of genetic testing—diagnostic testing, carrier testing, prenatal testing, consumer-oriented genetic testing, etc.—few issues loom ...

For pharmaceutical and biotechnology companies focusing on research and development, prioritizing data transparency and clinical study reporting (CSR) is a ...

The 11th annual Bio Supply Management Alliance (BSMA) conference brought together leaders from across the life sciences supply chain community ...

Why have value-based arrangements been so slowly adopted in life sciences industries? What might the future model look like? These ...

Pharmaceutical organizations looking to grow into personalized medicine are leveraging high-dollar acquisitions of cell therapy companies to quickly enter the ...

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference therapeutics for genetically ...

The shift to personalized medicine, where companies can develop preventive measures and precision treatments to enhance a patient’s unique well-being, ...